The race to bring new drugs and cell therapies like CAR-T to market is more intense than ever. Patients are waiting, and developers face mounting pressure to accelerate timelines, reduce costs, and meet evolving regulatory demands—all without compromising quality. Unfortunately, commonly used controls like engineered cell lines or donor-derived blood cells introduce variability and operational […]